Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1628 1629 1691
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17771737 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17232397 | METHOD FOR OBTAINING INFORMATION ON RISK OF REDUCED RESPIRATORY FUNCTION IN PATIENT WITH INTERSTITIAL PNEUMONIA | Final Rejection | SYSMEX CORPORATION |
| 16483548 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
| 17781778 | DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH | Non-Final OA | Toray Industries, Inc. |
| 18001519 | T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18009312 | Compositions Comprising Antimicrobials and (Bio)-Alkanediols for Skin Protection | Non-Final OA | Symrise AG |
| 15779416 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | Final Rejection | SYMRISE AG |
| 17060939 | HEAT SHOCK PROTEIN (HSP) INHIBITION AND MONITORING EFFECTIVENESS THEREOF | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18672929 | METHODS FOR TREATING MUCOPOLYSACCHARIDOSIS | Non-Final OA | University of Miami |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | Final Rejection | Gilead Sciences, Inc. |
| 18620058 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | Non-Final OA | VIVUS LLC |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Final Rejection | Dompe' farmaceutici SpA |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | Non-Final OA | Children's Medical Center Corporation |
| 17923532 | PROGESTOGEN FORMULATIONS AND USES THEREOF | Non-Final OA | Shenzhen Evergreen Therapeutics Co., Ltd |
| 18027229 | PHARMACEUTICAL COMPOSITION | Final Rejection | CB21 PHARMA, S.R.O. |
| 18040508 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES | Final Rejection | PALOBIOFARMA, S.L. |
| 15734843 | TARGETED TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER NEUROLOGICAL OR PSYCHIATRIC DISORDERS | Final Rejection | Auttx, LLC |
| 17059297 | NUPR1 INHIBITION FOR TREATING CANCER | Final Rejection | CONSIGLIO NAZIONALE DELLE RICERCHE- NATIONAL RESEARCH COUNCIL ITALY |
| 17051625 | In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate | Final Rejection | IVIEW Therapeutics (Zhuhai) Co., Ltd. |
| 16936769 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | Final Rejection | CAAMTECH LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy